Le Lézard
Classified in: Health
Subjects: LAW, PER

Mctlaw Partner Ilyas Sayeg Named Co-Lead Counsel of Consolidated Exactech Hip Knee and Ankle Lawsuits in Florida

Attorney Ilyas Sayeg, of mctlaw, has been appointed co-lead of the consolidated Exactech lawsuits in Florida's Eighth Judicial Circuit (Case No. 01-2022-CA-2670). These lawsuits involve patients dealing with the effects of Exactech's recalled hip, knee, and ankle implants. In his role as co-lead counsel, Mr. Sayeg will lead the implementation of the litigation plan, attend all status conferences and hearings, and submit all motions and matters. These duties are incredibly important to continue moving the case along in order to help patients get compensation.

SARASOTA, Fla., Sept. 25, 2022 /PRNewswire-PRWeb/ -- The Court overseeing the consolidated Exactechlawsuits in Florida's Eighth Judicial Circuit has appointed attorney Ilyas Sayeg, partner at mctlaw, as "Co-Lead" of the litigation (Case No. 01-2022-CA-2670). In his role as co-lead counsel, Mr. Sayeg will attend the status conferences and hearings, submit all motions and matters, and lead the implementation of the litigation plan. These duties are incredibly important to continue moving the case along in order to help Exactech plaintiffs get compensation. Previously, Ilyas Sayeg won the arguments to consolidate all of the FL Exactech cases into one master case, with the first trial date set for next year.

These lawsuits involve patients with Exactech's recalled hip, knee, and ankle implants. Exactech's own recall notices admit that the devices have the potential for "premature wear" of the plastic parts and "out-of-specification" packaging that can degrade the polyethylene in the implants.

The legal team at mctlaw is leading the way in this national litigation and is committed to helping clients get justice in their Exactech hips, knees, and ankles claims. Our attorneys have decades of experience litigating complex medical device cases and getting compensation for our clients. Whether you believe you have been hurt by a recalled Exactech device, or you represent such a person and are seeking an attorney to refer or co-counsel, we are happy to review your case.

About mctlaw
Florida-based mctlaw is a national leader in defective joint replacement litigation and has successfully represented clients with defective implants across the country. Our attorneys filed the first metal-on-metal hip lawsuit in the United States. Our tech-forward approach gives us an edge in preparing these cases for trial and leveraging that preparation for the best possible outcomes. The trial lawyers at mctlaw have over a century and a half of combined legal experience. We have recovered hundreds of millions of dollars in compensation for our clients. The legal team at mctlaw is licensed to practice law in state, federal, district, and circuit courts throughout the nation.

Media Contact

Ilyas Sayeg, mctlaw, 1 8889525242, gdennis@mctlaw.com


SOURCE mctlaw

These press releases may also interest you

at 02:00
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland's Euformatics and Hungary's Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the...

at 02:00
The teleradiology market size is forecasted to increase by USD 2,804.51 million from 2022 to 2027, at a CAGR of 15.52%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of...

at 01:46
Encore Medical Education, a US-based medical education company will launch the 2022 edition of the Best of SABCS® News Highlights program from the 2022 San Antonio Breast Cancer Symposium (SABCS®) starting December 7th. This official SABCS® News...

at 00:29
Cadence Education, LLC. ("Cadence Education"), one of the largest providers of early childhood education in North America, announced that its 2022 annual company-wide fundraising St. Jude Trike-A-Thon event has raised $330,145. This brings Cadence...

at 00:00
This webinar will enable attendees to understand and comply with the FDA's cell and gene therapy...

30 nov 2022
IVERIC bio, Inc. (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition,...

News published on 25 september 2022 at 16:20 and distributed by: